Mega merger alert: Kimberley-Clark to acquire Kenvue for over $40 billion as Tylenol — What’s inside the deal?

Mega merger alert: Kimberley-Clark to acquire Kenvue for over billion as Tylenol — What’s inside the deal?

Consumer products and personal care giant Kimberley-Clark is buying Tylenol maker Kenvue in a $40 billion deal involving stock and cash in what could be called a massive merger of two consumer health products companies.

The landmark deal for the consumer industry comes as Kenvue’s flagship drug, Tylenol, faces White House scrutiny and fluctuating demand.

With the merger, Kimberley-Clark will surpass Unilever and become the second largest company selling health and wellness products, after Procter & Gamble Co.

What’s included in the $40 billion Kenvue-Kimberley Clark deal?

Kenvue shareholders received $3.50 per share in cash and 0.14625 Kimberly-Clark shares per Kenvue share, the companies said in a statement Monday. This translates into an equity value of $40.32 billion, according to calculations by Reuters.

Also Read | J&J and Kenvue sued by Texas weeks after Trump claimed Tylenol causes autism

With cash and stock, the value of the deal comes to $21.01 per share. This represents a significant premium of 46.2% over the last closing price of Kenvue shares.

The enterprise value of the deal is about $48.7 billion, the companies said.

Kimberley-Clark’s existing shareholders will own approximately 54% of the combined companies, while Kenvue shareholders will receive the remaining 46%.

The deal is expected to be completed in the second half of 2026. After the merger, Mike Hsu will continue as CEO according to the terms of the agreement.

Also Read | Does Tylenol cause Autism? Here’s how we can learn

“Kimberly-Clark has undertaken a significant transformation to reorient our portfolio towards higher-growth, higher-margin businesses,” Hsu said in a statement, adding that Kenvue’s collection of brands fits that bill.

Shares of Kimberly-Clark, which owns the Kleenex and Huggies brands, fell 16% in premarket trading. Meanwhile, shares of Kenvue rose 19%.

Kimberly-Clark expects annual cost savings of approximately $2.1 billion from the acquisition.

Timing of Kenvue-Kimberley Clark deal

While reports of a possible acquisition have been circulating in the media since June, the timing of the Kenvue-Kimberley Clark deal came earlier than expected.

Kenvue is struggling with declining demand and faces scrutiny from the White House following allegations that Tylenol causes autism and ADHD in children if their mothers consume the drug while pregnant.

Last week, U.S. Health and Human Services Secretary Robert F. Kennedy Jr. acknowledged that there is no evidence proving Tylenol causes autism, but repeated his view that signs of a link between the two are “very telling.”

Also Read | Tylenol Maker Kenvue Faces Increasing Crisis After Trump Outburst

But that doesn’t seem to have done much good for the company, which has faced lawsuits over allegations that its baby powder products cause cancer, dampening investor sentiment.

Kenvue has struggled since it was spun off from Johnson & Johnson two years ago, with the firm having had a relatively short time as an independent company.